OR WAIT null SECS
Agreement aims to speed up the launch of endometriosis and androgenic alopecia treatment.
Chime Biologics, a contract development and manufacturing organization (CDMO), and Hope Medicine, a clinical-stage biotech company, announced plans to collaborate on development and manufacturing of monoclonal antibody drug HMI-115. As per the agreement, Chime Biologics will provide CMC solution for the biotech’s drug candidate, hoping to speed up the process of a potential launch for treatment of endometriosis and androgenetic alopecia.
"We are pleased to be a strategic partner of Hope Medicine. We are fully committed to driving the commercialization of HMI-115 mAb for the treatment of endometriosis and androgenetic alopecia to ensure the successful launch of this novel antibody drug,” said Jimmy Wei, president, Chime Biologics. “Currently, Chime Biologics has completed several late-stage CMC projects and is also in the process of commercial manufacturing for several post-market drugs. We are proud to empower our global partners to deliver clinical value for the benefit of patients."
Reference: Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia. PR Newswire. October 26, 2023. Accessed October 26, 2023. https://www.prnewswire.com/news-releases/chime-biologics-and-hope-medicine-enter-manufacturing-agreement-to-speed-up-the-launch-of-first-in-class-antibody-drug-hmi-115-targeting-endometriosis-and-androgenic-alopecia-301968968.html